Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74380 | 1.00 | HTR6 (0.60) | HTR6TRPV4NFE2L2KCNH2CA12 | |
| SCHEMBL31387938 | 0.82 | TRPV4 (0.42) | HTR6TRPV4NFE2L2KCNH2CA12 | |
| SCHEMBL7205989 | 0.82 | TRPV4 (0.42) | HTR6TRPV4NFE2L2KCNH2CA12 | |
| SCHEMBL31352974 | 0.82 | HTR6 (0.77) | HTR6NFE2L2KCNH2CA12CA1 | |
| SCHEMBL29969255 | 0.82 | TRPV4 (0.49) | HTR6TRPV4NFE2L2KCNH2CA12 | |
| SCHEMBL1713241 | 0.82 | TRPV4 (0.49) | HTR6TRPV4NFE2L2KCNH2CA12 | |
| SCHEMBL22980481 | 0.82 | TRPV4 (0.53) | HTR6TRPV4NFE2L2KCNH2CA12 | |
| SCHEMBL5984084 | 0.82 | TRPV4 (0.49) | HTR6TRPV4NFE2L2KCNH2CA12 | |
| 1,2-Dimethoxybenzene SCHEMBL66189 | 0.81 | CA1 (0.68) | HTR6TRPV4NFE2L2CA12CA1 | |
| SCHEMBL29651874 | 0.80 | TRPV4 (0.47) | HTR6TRPV4NFE2L2KCNH2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661966-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | Type6 Therapeutics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4499609-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192817-A9 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-4433474-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024175450-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024167848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | TYPE6 THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4337203-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Syndax Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023192817-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023088233-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-25 | — | — | WO | disclosed |
| EP-4181920-A1 | KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT | Pfizer Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022241265-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022199367-A1 | DITHIOCARBAMATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | 北京大学 | 2022-09-29 | — | — | WO | disclosed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
| EP-3986890-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | HTR6 2434/4885TRPV4 3928/4885NFE2L2 2623/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HTR6 2254/4885TRPV4 1576/4885NFE2L2 1578/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | HTR6 535/4885TRPV4 2033/4885NFE2L2 2594/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | HTR6 4676/4885TRPV4 2125/4885NFE2L2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.